Bacil Pharma Result: Profit ka Jhol? Core Sales Zero, Paisa Kahan Se Aaya?

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAarav Shah|Published at:
Bacil Pharma Result: Profit ka Jhol? Core Sales Zero, Paisa Kahan Se Aaya?
Overview

Bacil Pharma Limited ne Q3 FY26 mein profit report kiya hai, but yeh sara profit 'Other Income' se aaya hai. Company ke core business se revenue bilkul **₹0** raha.

Arey yaar, yeh Bacil Pharma ka kya chal raha hai?

Company ne Q3 FY26 results announce kiye hain aur unka kehna hai ki woh ab profit mein aa gaye hain. Sirf ₹0.0392 Crore ka PAT (Profit After Tax) dikhaya hai. Lekin asli kahani toh kuch aur hi hai!

Toh, yeh profit aaya kahan se? (The Real Story)

Jab numbers dekhe toh pata chala ki yeh sara kamaal 'Other Income' ka hai. Yeh 'Other Income' pichle saal ke comparison mein 1050% tadka laga kar ₹0.0645 Crore ho gaya hai. Jabki company ke main kaam, matlab 'Revenue from operations' se toh ₹0 hi revenue aaya hai, Q3 mein bhi aur toh aur 9 mahine mein bhi ₹0 hi raha! Expenses bhi 61.08% kam ho gaye, jisse loss se profit mein shift dikh raha hai.

Par sab kuch itna acha nahi hai! (The Catch)

Chalo, Q3 mein loss se profit mein aana achi baat hai (pichhle saal ₹-0.0620 Crore ka loss tha). Basic EPS bhi ₹0.03 ho gaya hai. Lekin jab 9 mahine ke figures dekhte hain, toh ek choti si problem hai. Total PAT 85.96% badh kar ₹0.7217 Crore ho gaya hai, lekin EPS ₹0.66 se gir kar ₹0.52 ho gaya hai! Yeh kaise hua bhai? Aisa lag raha hai ki shares ki wajah se earnings per share kam ho gaya hai.

Toh investors ko kya dhyan dena chahiye? (Investor Alert!)

Sabse bada sawaal toh yahi hai ki agar company ka main business hi chal nahi raha (revenue ₹0 hai), toh yeh profit kitna tikega? Yeh 'Other Income' kya hai, kahan se aa raha hai aur kya yeh dobara aayega? Aur 9 mahine mein EPS kyun gira, jabki profit badh raha tha? Yeh sab cheezein samajhna investors ke liye bahut zaroori hai taaki company ki asli health ka pata chal sake.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.